Physician profile
Conrad J Tseng
NPI 1013924455
$17,154.78
in general payments reported to CMS, 2019-2025
57 companies · $33.80 in 2025
The $33.80 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,570 · 2020: $2,374 · 2021: $3,594 · 2022: $3,806 · 2023: $3,658 · 2024: $120 · 2025: $33.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,787 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,787.12 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,334.27 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $1,651.64 | 2019-2023 | Trulicity, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,380.99 | 2019-2023 | Jardiance, Tradjenta, Synjardy |
| Abbvie INC. | $1,153.06 | 2019-2023 | Ubrelvy, Synthroid |
| Insulet Corporation | $1,087.67 | 2019-2023 | Omnipod |
| Amgen INC. | $831.96 | 2019-2023 | Prolia, Evenity, Repatha |
| Sanofi-Aventis U.S. LLC | $826.24 | 2019-2023 | |
| Mannkind Corporation | $755.81 | 2019-2023 | Afrezza |
| Abbott Laboratories | $635.50 | 2019-2023 | Freestyle Libre 3 |
| Corcept Therapeutics | $567.50 | 2019-2023 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $560.39 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $489.48 | 2019-2023 | Farxiga |
| Radius Health, INC. | $485.30 | 2019-2025 | Tymlos |
| Merck Sharp & Dohme LLC | $476.79 | 2019-2021 | |
| Ibsa Pharma INC. | $352.71 | 2019-2023 | Tirosint, Licart |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Conrad Tseng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.